• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

趋化因子受体CXCR4的寡聚化被拮抗剂配体IT1t选择性破坏。

Chemokine receptor CXCR4 oligomerization is disrupted selectively by the antagonist ligand IT1t.

作者信息

Ward Richard J, Pediani John D, Marsango Sara, Jolly Richard, Stoneman Michael R, Biener Gabriel, Handel Tracy M, Raicu Valerică, Milligan Graeme

机构信息

Centre for Translational Pharmacology, Institute of Molecular, Cell and Systems Biology, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, Scotland, United Kingdom.

Physics Department, University of Wisconsin-Milwaukee, Milwaukee, Wisconsin, USA.

出版信息

J Biol Chem. 2021 Jan-Jun;296:100139. doi: 10.1074/jbc.RA120.016612. Epub 2020 Dec 6.

DOI:10.1074/jbc.RA120.016612
PMID:33268380
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7949023/
Abstract

CXCR4, a member of the family of chemokine-activated G protein-coupled receptors, is widely expressed in immune response cells. It is involved in both cancer development and progression as well as viral infection, notably by HIV-1. A variety of methods, including structural information, have suggested that the receptor may exist as a dimer or an oligomer. However, the mechanistic details surrounding receptor oligomerization and its potential dynamic regulation remain unclear. Using both biochemical and biophysical means, we confirm that CXCR4 can exist as a mixture of monomers, dimers, and higher-order oligomers in cell membranes and show that oligomeric structure becomes more complex as receptor expression levels increase. Mutations of CXCR4 residues located at a putative dimerization interface result in monomerization of the receptor. Additionally, binding of the CXCR4 antagonist IT1t-a small drug-like isothiourea derivative-rapidly destabilizes the oligomeric structure, whereas AMD3100, another well-characterized CXCR4 antagonist, does not. Although a mutation that regulates constitutive activity of CXCR4 also results in monomerization of the receptor, binding of IT1t to this variant promotes receptor dimerization. These results provide novel insights into the basal organization of CXCR4 and how antagonist ligands of different chemotypes differentially regulate its oligomerization state.

摘要

CXCR4是趋化因子激活的G蛋白偶联受体家族的一员,在免疫反应细胞中广泛表达。它参与癌症的发生和发展以及病毒感染,尤其是HIV-1感染。包括结构信息在内的多种方法表明,该受体可能以二聚体或寡聚体形式存在。然而,围绕受体寡聚化及其潜在动态调节的机制细节仍不清楚。我们通过生化和生物物理手段证实,CXCR4在细胞膜中可以以单体、二聚体和高阶寡聚体的混合物形式存在,并表明随着受体表达水平的增加,寡聚体结构变得更加复杂。位于假定二聚化界面的CXCR4残基发生突变会导致受体单体化。此外,CXCR4拮抗剂IT1t(一种类似药物的异硫脲衍生物)的结合会迅速破坏寡聚体结构,而另一种特征明确的CXCR4拮抗剂AMD3100则不会。虽然调节CXCR4组成型活性的突变也会导致受体单体化,但IT1t与该变体的结合会促进受体二聚化。这些结果为CXCR4的基础组织以及不同化学类型的拮抗剂配体如何差异调节其寡聚化状态提供了新的见解。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c4f4/7949023/f30b77d3589f/gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c4f4/7949023/9c9521d959a6/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c4f4/7949023/2b3d38dcbf7a/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c4f4/7949023/c19dc535deb7/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c4f4/7949023/52c33f2844e0/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c4f4/7949023/e63faf431549/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c4f4/7949023/f30b77d3589f/gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c4f4/7949023/9c9521d959a6/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c4f4/7949023/2b3d38dcbf7a/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c4f4/7949023/c19dc535deb7/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c4f4/7949023/52c33f2844e0/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c4f4/7949023/e63faf431549/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c4f4/7949023/f30b77d3589f/gr6.jpg

相似文献

1
Chemokine receptor CXCR4 oligomerization is disrupted selectively by the antagonist ligand IT1t.趋化因子受体CXCR4的寡聚化被拮抗剂配体IT1t选择性破坏。
J Biol Chem. 2021 Jan-Jun;296:100139. doi: 10.1074/jbc.RA120.016612. Epub 2020 Dec 6.
2
Characterization, Dynamics, and Mechanism of CXCR4 Antagonists on a Constitutively Active Mutant.结构特征、动力学和 CXCR4 拮抗剂对组成型激活突变体的作用机制。
Cell Chem Biol. 2019 May 16;26(5):662-673.e7. doi: 10.1016/j.chembiol.2019.01.012. Epub 2019 Feb 28.
3
Single-Molecule Imaging Demonstrates Ligand Regulation of the Oligomeric Status of CXCR4 in Living Cells.单分子成像显示配体调节 CXCR4 寡聚状态在活细胞中。
J Phys Chem B. 2017 Feb 23;121(7):1466-1474. doi: 10.1021/acs.jpcb.6b10969. Epub 2017 Feb 9.
4
Anti-HIV small-molecule binding in the peptide subpocket of the CXCR4:CVX15 crystal structure.抗HIV小分子在CXCR4:CVX15晶体结构的肽亚口袋中的结合情况。
Chembiochem. 2014 Jul 21;15(11):1614-20. doi: 10.1002/cbic.201402056. Epub 2014 Jul 2.
5
Advanced fluorescence microscopy reveals disruption of dynamic CXCR4 dimerization by subpocket-specific inverse agonists.高级荧光显微镜揭示了亚口袋特异性反向激动剂对 CXCR4 二聚化的动态破坏。
Proc Natl Acad Sci U S A. 2020 Nov 17;117(46):29144-29154. doi: 10.1073/pnas.2013319117. Epub 2020 Nov 4.
6
Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists.小分子和环肽拮抗剂与 CXCR4 趋化因子 GPCR 的结构。
Science. 2010 Nov 19;330(6007):1066-71. doi: 10.1126/science.1194396. Epub 2010 Oct 7.
7
Pathway and mechanism of drug binding to chemokine receptors revealed by accelerated molecular simulations.药物与趋化因子受体结合的途径和机制通过加速分子模拟揭示。
Future Med Chem. 2020 Jul;12(13):1213-1225. doi: 10.4155/fmc-2020-0044. Epub 2020 Jun 9.
8
Cu PET Imaging of the CXCR4 Chemokine Receptor Using a Cross-Bridged Cyclam Bis-Tetraazamacrocyclic Antagonist.使用交联环脒双四氮杂大环拮抗剂进行 CXCR4 趋化因子受体的 Cu-PET 成像。
J Nucl Med. 2020 Jan;61(1):123-128. doi: 10.2967/jnumed.118.218008. Epub 2019 Jun 14.
9
CXCR4 antagonism sensitizes cancer cells to novel indole-based MDM2/4 inhibitors in glioblastoma multiforme.CXCR4 拮抗作用使胶质母细胞瘤中的癌细胞对新型吲哚基 MDM2/4 抑制剂敏感。
Eur J Pharmacol. 2021 Apr 15;897:173936. doi: 10.1016/j.ejphar.2021.173936. Epub 2021 Feb 10.
10
The peptidomimetic CXCR4 antagonist TC14012 recruits beta-arrestin to CXCR7: roles of receptor domains.肽拟态趋化因子受体 4 拮抗剂 TC14012 募集β-arrestin 到趋化因子受体 7:受体结构域的作用。
J Biol Chem. 2010 Dec 3;285(49):37939-43. doi: 10.1074/jbc.C110.147470. Epub 2010 Oct 18.

引用本文的文献

1
Disruption of constitutive CXCR4 oligomers impairs oncogenic properties in lymphoid neoplasms.组成型CXCR4寡聚体的破坏会损害淋巴瘤的致癌特性。
Proc Natl Acad Sci U S A. 2025 Jun 17;122(24):e2424186122. doi: 10.1073/pnas.2424186122. Epub 2025 Jun 11.
2
Targeting the chemokine receptor CXCR4 for cancer therapies.以趋化因子受体CXCR4为靶点进行癌症治疗。
Biomark Res. 2025 May 1;13(1):68. doi: 10.1186/s40364-025-00778-y.
3
Functional dynamics of G protein-coupled receptors reveal new routes for drug discovery.G蛋白偶联受体的功能动力学揭示了药物发现的新途径。

本文引用的文献

1
Advanced fluorescence microscopy reveals disruption of dynamic CXCR4 dimerization by subpocket-specific inverse agonists.高级荧光显微镜揭示了亚口袋特异性反向激动剂对 CXCR4 二聚化的动态破坏。
Proc Natl Acad Sci U S A. 2020 Nov 17;117(46):29144-29154. doi: 10.1073/pnas.2013319117. Epub 2020 Nov 4.
2
CXCR4 antagonist AMD3100 (plerixafor): From an impurity to a therapeutic agent.CXCR4拮抗剂AMD3100(普乐沙福):从杂质到治疗药物。
Pharmacol Res. 2020 Sep;159:105010. doi: 10.1016/j.phrs.2020.105010. Epub 2020 Jun 13.
3
Reply to: Spatial heterogeneity in molecular brightness.
Nat Rev Drug Discov. 2025 Apr;24(4):251-275. doi: 10.1038/s41573-024-01083-3. Epub 2025 Jan 2.
4
Pulse Activation of Retinoic Acid Receptor Enhances Hematopoietic Stem Cell Homing by Controlling CXCR4 Membrane Presentation.视黄酸受体的脉冲激活通过控制CXCR4膜表达增强造血干细胞归巢
Stem Cell Rev Rep. 2025 Jan;21(1):68-79. doi: 10.1007/s12015-024-10813-4. Epub 2024 Oct 31.
5
Structural insights into CXCR4 modulation and oligomerization.对CXCR4调节和寡聚化的结构见解。
Nat Struct Mol Biol. 2025 Feb;32(2):315-325. doi: 10.1038/s41594-024-01397-1. Epub 2024 Sep 23.
6
Interaction and dynamics of chemokine receptor CXCR4 binding with CXCL12 and hBD-3.趋化因子受体CXCR4与CXCL12和人β-防御素3的相互作用及动力学
Commun Chem. 2024 Sep 13;7(1):205. doi: 10.1038/s42004-024-01280-6.
7
Identifying and Assessing Putative Allosteric Sites and Modulators for CXCR4 Predicted through Network Modeling and Site Identification by Ligand Competitive Saturation.通过网络建模和配体竞争饱和鉴定预测 CXCR4 的潜在变构结合位点和调节剂。
J Phys Chem B. 2024 May 30;128(21):5157-5174. doi: 10.1021/acs.jpcb.4c00925. Epub 2024 Apr 22.
8
CXCL17 is an allosteric inhibitor of CXCR4 through a mechanism of action involving glycosaminoglycans.CXCL17 通过涉及糖胺聚糖的作用机制,成为 CXCR4 的别构抑制剂。
Sci Signal. 2024 Mar 19;17(828):eabl3758. doi: 10.1126/scisignal.abl3758.
9
Crosstalk between purinergic receptor P2Y and chemokine receptor CXCR7 is regulated by CXCR4 in human macrophages.嘌呤能受体P2Y与趋化因子受体CXCR7之间的串扰由人类巨噬细胞中的CXCR4调控。
Cell Mol Life Sci. 2024 Mar 13;81(1):132. doi: 10.1007/s00018-024-05158-7.
10
Structural basis of dimerization of chemokine receptors CCR5 and CXCR4.趋化因子受体 CCR5 和 CXCR4 二聚化的结构基础。
Nat Commun. 2023 Oct 13;14(1):6439. doi: 10.1038/s41467-023-42082-z.
回复:分子亮度的空间异质性
Nat Methods. 2020 Mar;17(3):276-278. doi: 10.1038/s41592-020-0735-x. Epub 2020 Feb 10.
4
Resolving fluorescent species by their brightness and diffusion using correlated photon-counting histograms.利用相关光子计数直方图根据亮度和扩散来分辨荧光物种。
PLoS One. 2019 Dec 30;14(12):e0226063. doi: 10.1371/journal.pone.0226063. eCollection 2019.
5
From Insight to Modulation of CXCR4 and ACKR3 (CXCR7) Function.从洞察到 CXCR4 和 ACKR3(CXCR7)功能的调节。
Mol Pharmacol. 2019 Dec;96(6):735-736. doi: 10.1124/mol.119.118364. Epub 2019 Oct 17.
6
A general method to quantify ligand-driven oligomerization from fluorescence-based images.一种从基于荧光的图像定量分析配体驱动寡聚化的通用方法。
Nat Methods. 2019 Jun;16(6):493-496. doi: 10.1038/s41592-019-0408-9. Epub 2019 May 20.
7
Cryo-EM structures of GPCRs coupled to G, G and G.GPCR 与 G、G 和 G 偶联的冷冻电镜结构
Mol Cell Endocrinol. 2019 May 15;488:1-13. doi: 10.1016/j.mce.2019.02.006. Epub 2019 Mar 28.
8
Characterization, Dynamics, and Mechanism of CXCR4 Antagonists on a Constitutively Active Mutant.结构特征、动力学和 CXCR4 拮抗剂对组成型激活突变体的作用机制。
Cell Chem Biol. 2019 May 16;26(5):662-673.e7. doi: 10.1016/j.chembiol.2019.01.012. Epub 2019 Feb 28.
9
Using enhanced number and brightness to measure protein oligomerization dynamics in live cells.利用增强的数量和亮度来测量活细胞中蛋白质寡聚体的动态变化。
Nat Protoc. 2019 Feb;14(2):616-638. doi: 10.1038/s41596-018-0111-9.
10
Shaky ground - The nature of metastable GPCR signalling complexes.摇摇欲坠的基础——不稳定 G 蛋白偶联受体信号复合物的本质。
Neuropharmacology. 2019 Jul 1;152:4-14. doi: 10.1016/j.neuropharm.2019.01.018. Epub 2019 Jan 17.